FDA Trust Collapses Amid Political Interference Claims

Trust in the U.S. Food and Drug Administration (FDA) has significantly declined, with approximately half of Americans expressing confidence, a sharp drop from roughly 75% two years prior. This erosion of trust is attributed not to a lack of competence, but to concerns about the agency's independence. A recent KFF tracking poll indicated that fewer than half of respondents believe the FDA can make decisions free from political interference. Furthermore, a Harvard survey conducted in June 2026 revealed that a majority of Americans perceive federal health recommendations as overly influenced by leaders' personal beliefs rather than scientific evidence.

A substantial portion of this decline in trust is linked to statements and actions by HHS Secretary Robert F. Kennedy Jr., who oversees the FDA. Kennedy has publicly described the agency as "corrupt," alleged it prioritizes industry interests over public health, and advocated for revisiting established scientific positions. This internal tension has manifested in recent events, such as the FDA's own scientists recommending stricter oversight for peptide therapies in June, while Kennedy pushed for deregulation. This situation exemplifies political leadership potentially overriding the professional judgment of career scientists within the agency.

Restoring public confidence in the FDA necessitates a dedicated and ongoing effort focused on transparency, consistency in decision-making, scientific integrity, accountability for actions, and modernization of its processes. By achieving these objectives, the agency can bolster both public health outcomes and America's standing in the field of biomedical innovation. A revitalized FDA would ensure that life-saving scientific advancements are effectively translated into public benefits through a system that commands and deserves public trust, echoing the historical emphasis on science as a national asset.